 We are initiating coverage of Cardiff Oncology CRDF with a VERY BULLISH rating at a 30 PT. We project a worldwide peak sales north of US1bn for mCRC indication only. CRDF shares have been steadily increasing since late Q2, with catalysts including robust clinical data of Onvansertib in mCRC, as well as complete corporate restructuring and re-branding earlier this year. 